ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tegoprazan

Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.

Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.

Drug pageTegoprazan: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 13, 202048 company-led studies, 7 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.Nits history only376 open or runningphase 4since Mar 13, 2020Nov 14, 2011Jan 31, 2027phase 1 · NCT07853248
Shandong Luoxin Pharmaceutical Group Stock70 open or runningphase 3since Jul 9, 2018Jan 25, 2018none ahead
Sebela Pharmaceuticalsits history only30 open or runningphase 3since Oct 17, 2022Oct 17, 2022none ahead
Carnot Laboratoriesits history only11 open or runningphase 4since May 20, 2025May 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shandong Luoxin Pharmaceutical Group Stock only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named tegoprazanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BLI5100
  2. Jan 25, 2018First study: phase 1 study in HealthyFirst studyNCT03458650 · 38 enrolled · China
  3. Jul 9, 20182 phase 3 studiesNCT03615677, NCT03591653
  4. Aug 11, 2021Phase 3 study in Duodenal UlcerNCT05010954 · 400 enrolled · China
  5. Oct 9, 2022Phase 3 study in Helicobacter Pylori InfectionNCT05577468 · 561 enrolled · China
  6. May 10, 2023Phase 1 study in Healthy SubjectsNCT05883306 · 6 enrolled · China
  7. Jun 2, 2023Phase 1 study in HealthyNCT05915871 · 22 enrolled · China

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 7 Shandong Luoxin Pharmaceutical Group Stock leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05915871Healthy · China1CompletedApr 28, 202322
NCT05883306Healthy Subjects · China1CompletedJul 21, 20226
NCT05577468Helicobacter Pylori Infection · China3CompletedSep 30, 2023561
NCT05010954Duodenal Ulcer · China3CompletedSep 28, 2022400
NCT03615677Erosive Esophagitis (EE) · China3CompletedOct 18, 2019261
NCT03591653Non-Erosive Reflux Disease · China3CompletedOct 30, 2019291
NCT03458650Healthy · China1CompletedApr 23, 201838

How it is read

Names in the registry

  • “Tegoprazan”, 10 entries
  • “Tegoprazan 50 mg”, 5 entries
  • “BLI5100”, 3 entries
  • “Tegoprazan 50mg”, 3 entries
  • “CJ-12420 50mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.